For retatrutide , Phase 2 trial data published in the New England Journal of Medicine (2023) demonstrated highly significant weight loss outcomes in adults with obesity (without type 2 diabetes)
Bellezza I, Giambanco I, Minelli A, Donato R
[DOI] [PubMed] [Google Scholar] 35.Pacanowski M.A., Frye R.F., Enogieru O., Schofield R.S., Zineh I
The complexities arise from Section 503A of the Federal Food, Drug, and Cosmetic Act, which relates to the necessary conditions for drug compounding.20 The rules concerning the compounding of therapeutic peptides state that they must come from accredited compounding pharmacies, and the compounded drug must either be compounded from an existing FDA-approved drug product or use drug products included on the 503A bulks list (i.e., the FDAs roster of compoundable substances.)21 But many therapeutic peptides dont satisfy either of the 503A conditions
Will I purchase
References 1 RossDSBurchHBCooperDSGreenleeMCLaurbergPMaiaALet al